In short: The arb's terminal event, noted in passing. "ATAI, the deal is expected to close on September 11th, so that likely closed." The deck adds the NASDAQ trader alert: halted after the after-hours session on September 10, closing before the open on September 11, and suspended effective September 14 — two days later than the September 9 date given on the prior call.
Full passage: premium transcript (PDF).
In short: An arb reaching its terminal event, kept in the book only as a calendar item. "ATAI is set to close on Wednesday." The deck adds the mechanics from the NASDAQ trader alert: the merger is tentatively scheduled to close before the market open on September 9, 2026, with the stock halted immediately following the after-hours session at around 7:50pm on September 8. Nothing left to underwrite — the spread is the last few days of carry.
ATAI is a merger-arbitrage position that has run its course. The acquisition is scheduled to complete before the market opens on Wednesday 9 September, and the stock will stop trading after Tuesday's after-hours session, at around 7:50pm, so shareholders receive the deal consideration instead of a share price.
There is nothing left to analyse. Once a deal is days from closing, the remaining gap between the market price and the payout is just a few days' worth of interest — the return for holding cash that is about to be released. It appears on the call as a calendar item rather than an idea, which is exactly the right way to treat it.
Full passage: premium transcript (PDF).
In short: "ATAI will also hold a shareholder vote on September 8th" — the definitive proxy is filed, HSR expires Aug 28, the Australian ACCC application expires Sept 16, and the merger is expected to close in Q3 2026.
Full passage: premium transcript (PDF).
In short: +33% Thu on a definitive agreement to be acquired by Eli Lilly for $6.75 cash + up to $2.50 per-share CVR (contingent value right). A realized special-situation win on the psychedelics/CNS name (post the Beckley Psytech combination).
A merger-arbitrage win that already paid off: atai (a mental-health/psychedelics drug developer) jumped 33% when Eli Lilly signed a firm agreement to buy it for $6.75 a share in cash, plus up to another $2.50 a share in a "CVR" — a contingent payment you only collect if the drugs hit certain milestones. It's a done deal (definitive), so this is Singh reporting a special-situation that worked rather than a fresh idea.
Full passage: premium transcript (PDF).
Nothing matches this filter.
Verbatim excerpts from the public transcripts (auto-pulled at each mention's timestamp, lightly cleaned). Timestamps link into the video; "source page" opens that commentator's full analysis at this row. Click a mention's header line to expand it (one open at a time). For personal study — not investment advice.